The benefit gained from using the device for the performance the manufacturer intends must be greater than any undesirable effects of its use. Side effects and adverse outcomes are weighed in the clinical evaluation, which regulation 3.11 requires to demonstrate this principle in particular, and the conclusion must be revisited as post-market data arrives.
The graph holds this control, the 0 it maps to, and the evidence behind each claim, over MCP and REST.